Association of CDC25 phosphatase family polymorphisms with the efficacy/toxicity of platinum-based chemotherapy in Chinese advanced NSCLC patients. (May 2014)

• Record Type: Journal Article
• Authors: Cai, Weijing; Chen, Chang; Li, Xinzheng; Shi, Jinyun; Sun, Qian; Liu, Di; Sun, Yifeng; Hou, Likun; Zhao, Xueying; Gu, Shaohua; Wu, Qihan; Chen, Hongyan; Zhang, Wei; Jin, Li; Lu, Daru; Fei, Ke; Su, Bo; Qian, Ji
• Is Part Of: Future oncology. Volume 10:Number 7(2014)
• Page Start: 1175
• Page End: 1185
• Publication Date: 2014-05
• Subjects: CDC25 family -- chemotherapy -- lung cancer -- platinum -- single nucleotide polymorphism; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.14.25
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT: : Aim: To explore relationships between single nucleotide polymorphisms (SNPs) of the CDC25 protein family and the survival and chemotherapy responses of patients with advanced non-small-cell lung cancer (NSCLC).Methods & materials: We genotyped 14 SNPs of the CDC25 family in 663 Chinese patients with advanced NSCLC who were treated with first-line platinum-based chemotherapy and, in evaluable patients, analyzed relationships between the CDC25 family and the efficacy of platinum-based chemotherapy.Results: CDC25A rs3731513 and rs1380053, CDC25C rs6861656, CDC25A haplotype T/A/A/A/C and CDC25C haplotype A/G/G/G/C were significantly associated with the patients' progression-free survival. In addition, CDC25B rs3761218 and haplotype G/T/G/G were associated with the occurrence of severe toxicity with platinum-based chemotherapy, especially gastrointestinal and hematological toxicity.Conclusion: These findings reveal a relationship between genetic variations of the CDC25 family and the efficacy and toxicity of platinum-based chemotherapy in patients with advanced NSCLC, especially in those with non-squamous-cell carcinoma.